指南与共识血液淋巴病理细胞病理与分子病理

间变性大细胞淋巴瘤DUSP22 FISH结果不确定:临床报告与诊断评估建议

Anaplastic large cell lymphomas with equivocal DUSP22 FISH results: recommendations for clinical reporting and diagnostic evaluation.
指南 / 共识 · Hum Pathol · 2023-08-24

该指南针对间变性大细胞淋巴瘤(ALCL)中DUSP22断裂分离FISH结果不确定(BAP-FISHEQ)的病例,提出临床报告建议。研究显示BAP-FISHEQ病例临床病理异质,中位生存105个月,介于BAP-FISHPOS和BAP-FISHNEG之间。建议将BAP-FISHEQ报告为不确定,不归入阳性组,并可采用IHC算法辅助基因分型。

要点

  • DUSP22 BAP-FISHEQ ALCL应报告为不确定,不应与BAP-FISHPOS归为一组。
  • IHC算法(TIA1、pSTAT3Y705、LEF1)可预测DUSP22重排,辅助分型。
  • t(6;7) D-FISH可补充检测,有助于约三分之二的BAP-FISHEQ病例基因分型。

核心结论

  • BAP-FISHEQ ALCL临床病理异质,可能混合不平衡重排和局灶缺失无重排病例。
  • 建议将DUSP22 BAP-FISHEQ报告为不确定,不与BAP-FISHPOS ALCL归组。

研究设计与样本

  • 指南类文件,基于对37例BAP-FISHEQ ALCL的IHC算法和D-FISH检测分析。

主要发现

  • 37例BAP-FISHEQ ALCL中,18例(49%)IHC算法阳性,8例(21%)阴性,11例(30%)不确定。
  • 32例BAP-FISHEQ中,D-FISH在10/18例IHC阳性中阳性(56%),在0/9例IHC不确定和0/5例IHC阴性中阳性(0%)。
  • BAP-FISHEQ ALCL中位生存105个月,介于BAP-FISHPOS(中位未达到)和BAP-FISHNEG(19个月)之间。

关键数值与推荐

  • 推荐DUSP22 BAP-FISHEQ ALCL报告为不确定,不归入BAP-FISHPOS。
  • 临床采用IHC算法,可能补充t(6;7) D-FISH,可促进约三分之二BAP-FISHEQ ALCL的基因分型。

临床怎么用

  • 对DUSP22 BAP-FISH结果不确定的ALCL,应报告为不确定,避免误归为阳性。
  • 可应用TIA1、pSTAT3Y705、LEF1 IHC算法辅助预测DUSP22重排状态。
  • 必要时补充t(6;7) D-FISH检测,以协助基因亚型划分。

局限性

  • 研究样本量有限(37例BAP-FISHEQ),结论需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anaplastic large cell lymphoma (ALCL), one of the most common T-cell lymphomas, shows unifying pathological features but is clinically and genetically heterogeneous. One genetic subgroup, characterized by recurrent DUSP22 rearrangements (R), has distinct morphologic, immunophenotypic, and molecular features and can be identified in routine pathology practice using a breakapart (BAP) fluorescence in situ hybridization (FISH) probe. However, some cases show equivocal BAP-FISH findings (BAP-FISHEQ) and the features of these cases are poorly understood. Here, we sought to characterize DUSP22 BAP-FISHEQ ALCLs further. First, we applied an immunohistochemistry (IHC) algorithm using TIA1, pSTAT3Y705, and LEF1, which can predict DUSP22-R with high accuracy. Among 37 BAP-FISHEQ ALCLs, 18 (49%) were IHC-algorithm positive (IHCPOS), 8 (21%) were IHC-algorithm negative (IHCNEG), and 11 (30%) were IHCEQ. In 32 BAP-FISHEQ cases, we also applied a dual-color, dual-fusion (D-FISH) probe for t(6;7)(p25.3;q32.3), which accounts for 45% of DUSP22-R ALCLs. Among BAP-FISHEQ cases, D-FISH was positive in 10/18 IHCPOS cases (56%), 0/9 IHCEQ cases (0%), and 0/5 IHCNEG cases (0%). Median survival in BAP-FISHEQ ALCLs was 105 months, intermediate between BAP-FISHPOS ALCLs (median survival not reached) and BAP-FISHNEG ALCLs (19 months). Thus, DUSP22 BAP-FISHEQ ALCLs are clinicopathologically heterogeneous, likely due to an admixture of cases with an unbalanced DUSP22-R and cases with focal deletions without rearrangement. For clinical reporting, we recommend that DUSP22 BAP-FISHEQ ALCLs be reported as equivocal, and not be grouped with BAP-FISHPOS ALCLs. Clinical adoption of an IHC algorithm, possibly supplemented by t(6; 7) D-FISH, could facilitate genetic subtyping in about two-thirds of BAP-FISHEQ ALCLs.

来源:Hum Pathol,查看原文。版权归原作者所有。

引用

  1. Fadl A, Oishi N, Shi M, et al. Anaplastic large cell lymphomas with equivocal DUSP22 FISH results: recommendations for clinical reporting and diagnostic evaluation. Hum Pathol. 2023. PMID: 37633531. doi:10.1016/j.humpath.2023.08.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。